SANTA ANA, Calif.--(BUSINESS WIRE)--Irvine Scientific, a world leader in the innovation and manufacture of cell culture media, announced today the addition of three new serum-free media for the differentiation of mesenchymal stem/stromal cells into adipogenic, osteogenic, and chondrogenic lineages. These are the newest in the growing PRIME-XV® line of cell therapy products Irvine Scientific has developed to provide researchers the highest quality and performance media for the culture of human stem cells and primary cells. These media are manufactured under cGMP conditions in ISO13485 certified facilities to facilitate transition to clinical applications.
“Achieving robust differentiation and cell viability in serum-free media provides researchers the consistency and quality required for clinical studies,” says Dr. Rebecca Gilbert, R&D Director at Irvine Scientific. “We are committed to leveraging our expertise in media development to support rapid growth of cell therapy research.”
All three media are supplied in a time-saving, ready-to-use format and require no mixing of additional components.
- PRIME-XV® Osteogenic Differentiation SFM is a complete, serum-free medium that supports osteogenesis into osteoblasts and osteocytes.
- PRIME-XV® Chondrogenic Differentiation XSFM is a complete, xeno-free, and serum-free medium that supports chondrogenesis into chondrocytes.
- PRIME-XV® Adipogenic Differentiation SFM is a complete, serum-free medium that supports adipogenesis into adipocytes.
PRIME-XV cell therapy products provide a complete workflow solution from cell preservation to expansion and differentiation. View all the products at http://www.irvinesci.com/cell-therapy.
About Irvine Scientific
Irvine Scientific, a member of JX Holdings Group, is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 40 years Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.